reports
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Und...
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on October 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 78,975 shares of its common stock and granted an aggregate of 54,475 restricted stock unit (“RSU”) awards to 20 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducemen...
Texas Capital Bancshares, Inc. Announces Date for Q3 2025 Operating Re...
Texas Capital Bancshares, Inc. Announces Date for Q3 2025 Operating Results DALLAS, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital Bank, today announced that it expects to issue financial results for the third quarter of 2025 after market on Wednesday, October 22, 2025. Executive management will host a conference call and webcast to discuss third quarter 2025 operating results on Wednesday, October 22, 2025, at 5:00 p.m. EDT. Participants may pre-register for the call by visiting and will receive a unique PIN number t...
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Resul...
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 SAN DIEGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, November 6 at 4:30 p.m. ET Domestic:1 833-470-1428International:1 646-844-6383Access Code:166837 Webcast: Participants can use the dial-in numbers abov...
Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the T...
Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly Novel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy approved by the FDA to treat acromegaly Approval based on data from two pivotal Phase 3 trials where PALSONIFY was well tolerated and resulted in rapid, durable, and consistent biochemical control and reduced symptom burden Launch of lead product PALSONIFY marks a pivotal milestone for Crinetics as the premier endocrine-focused global pharmaceutical company Investor call to be...
Crinetics Pharmaceuticals Announces September 2025 Inducement Grants U...
Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on September 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 62,475 shares of its common stock and granted an aggregate of 43,800 restricted stock unit (“RSU”) awards to 20 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Ind...
Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the T...
Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH) SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate for the proposed treatment of classic congenital adrenal hyperplasia (CAH). Atumelnant is the first and only small molecule ACTH receptor antagonist in clinical development. “Receiving Orphan Drug Design...
Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Unde...
Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on August 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 75,850 shares of its common stock and granted an aggregate of 53,400 restricted stock unit (“RSU”) awards to 27 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement ...
Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Result...
Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update Regulatory Interactions and Commercial, Medical and Corporate Preparations On-Track for PALSONIFY™ (paltusotine) New Drug Application with September 25, 2025 PDUFA Date Continued Progress on the Global Development Program for Atumelnant Across Multiple Trials, Including the BALANCE-CAH Phase 2/3 Study for the Treatment of Children with Congenital Adrenal Hyperplasia Expected to Initiate this Year $1.2B in Cash, Cash Equivalents, and Investment Securities as of June 30, 2...
- Jonathan Moreland
MERC MERCER INTERNATIONAL INC.
CDXS CODEXIS
PETS PETMED EXPRESS INC.
CLRB CELLECTAR BIOSCIENCES
NHF NEXPOINT CREDIT STRATEGIES FUN
CZWI CITIZENS COMMUNITY BANCORP
LOOP LOOP INDUSTRIES
CHMG CHEMUNG FINANCIAL CORP.
FVCB FVCBANKCORP
FGBI FIRST GUARANTY BANCSHARES
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
CMTV COMMUNITY BANCORP INC. VT
DMAC DIAMEDICA THERAPEUTICS INC.
CRDF CARDIFF ONCOLOGY INC
IMRX IMMUNEERING CORP
NSPR INSPIREMD INC
BRCC BRC INC
LEXX LEXARIA BIOSCIENCE CORP
PMNT PERFECT MOMENT LTD.
DMA DESTRA MULTI ALTERNATIVE FUND
NYC NEW YORK CITY REIT
GF INC.
FGEN THE NEW GERMANY FUND
CCIF INC.
CVM FIBROGEN INC.
CARLYLE CREDIT INCOME FUND
CEL-SCI CORPORATION
Texas Capital Bancshares, Inc. Announces Quarterly Dividend for Prefer...
Texas Capital Bancshares, Inc. Announces Quarterly Dividend for Preferred Stock DALLAS, July 21, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital Bank, and its board of directors declared a cash dividend of $14.375 per share of the 5.75% Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series B (the “Series B Preferred Stock”), equivalent to $0.359375 per depositary share, each representing a 1/40th interest in a share of the Series B Preferred Stock. The depositary shares are traded on the NASDAQ under the symbol “TCBIO.” The...
Texas Capital Bancshares, Inc. Announces Second Quarter 2025 Results
Texas Capital Bancshares, Inc. Announces Second Quarter 2025 Results Second quarter 2025 net income of $77.3 million and net income available to common stockholders of $73.0 million, up 86% and 95%, respectively, year-over-year Second quarter 2025 EPS of $1.58 per diluted share and adjusted EPS(1) of $1.63 per diluted share, up 98% and 104%, respectively, year-over-year Strong balance sheet growth with total loans increasing 7% quarter-over-quarter and 10% year-over-year Book Value and Tangible Book Value(2) per share both increasing 13% year-over-year, reaching record levels DA...
Crinetics to Present New Long-Term Data Demonstrating Durable Control ...
Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025 Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label extensions of PATHFNDR-1 and PATHFNDR-2 studies Additional PALSONIFY presentations demonstrate reductions in patient-reported symptom burden, including both symptom severity and rates of symptom flares SAN DIEGO, July 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced new data from its clinical development program e...
Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Resu...
Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025 SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, August 7 @ 4:30 p.m. ET Domestic: 1 833-470-1428International: 1 404-975-4839Access Code: 899803 Webcast: Participants can use the dial-in number...
- Jonathan Moreland
Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under ...
Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, July 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on July 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 102,350 shares of its common stock and granted an aggregate of 77,875 restricted stock unit (“RSU”) awards to 46 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Pla...
Texas Capital Bancshares, Inc. Announces Date for Q2 2025 Operating Re...
Texas Capital Bancshares, Inc. Announces Date for Q2 2025 Operating Results DALLAS, July 03, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital Bank, today announced that it expects to issue financial results for the second quarter of 2025 before market on Thursday, July 17, 2025. Executive management will host a conference call and webcast to discuss second quarter 2025 operating results on Thursday, July 17, 2025, at 9:00 a.m. EDT. Participants may pre-register for the call by visiting and will receive a unique PIN number to b...
- Wedbush Research
HPP HUDSON PACIFIC PROPERTIES INC.
UMH UMH PROPERTIES INC.
UDR UDR INC.
TRNO TERRENO REALTY CORPORATION
STAG STAG INDUSTRIAL INC.
SBRA SABRA HEALTH CARE REIT INC.
RWT REDWOOD TRUST INC.
REXR REXFORD INDUSTRIAL REALTY INC.
OHI OMEGA HEALTHCARE INVESTORS INC.
OFC CORPORATE OFFICE PROPERTIES TRUST
NHI NATIONAL HEALTH INVESTORS INC.
MAA MID-AMERICA APARTMENT COMMUNITIES INC.
LTC LTC PROPERTIES INC.
WELL WELLTOWER INC.
FR FIRST INDUSTRIAL REALTY TRUST INC.
ESS ESSEX PROPERTY TRUST INC.
EQR EQUITY RESIDENTIAL
EGP EASTGROUP PROPERTIES INC.
CTRE CARETRUST REIT INC
CPT CAMDEN PROPERTY TRUST
BXP BOSTON PROPERTIES INC.
AVB AVALONBAY COMMUNITIES INC.
ARE ALEXANDRIA REAL ESTATE EQUITIES INC.
NFLX NETFLIX INC.
7974 NINTENDO CO. LTD.
PLYM PLYMOUTH INDUSTRIAL REIT INC.
ROKU ROKU INC. CLASS A
VTR VENTAS INC.
AMZN AMAZON.COM INC.
RC READY CAPITAL CORPORATION
SAFE SAFEHOLD INC.
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
DDOG DATADOG INC CLASS A
PEAK HEALTHPEAK PROPERTIES INC.
CSR CENTERSPACE
TTD THE TRADE DESK
HR INC.
STRW HEALTHCARE TRUST OF AMERICA INC.
STRAWBERRY FIELDS REIT INC.
- Jonathan Moreland
MMLP MARTIN MIDSTREAM PARTNERS L.P.
MERC MERCER INTERNATIONAL INC.
CDXS CODEXIS
PZG PARAMOUNT GOLD NEVADA CORP.
IRIX IRIDEX CORP.
VFF VILLAGE FARMS INTERNATIONAL IN
UEIC UNIVERSAL ELECTRONICS INC.
VRA VERA BRADLEY INC.
CIA CITIZENS INC. CL A
FLL FULL HOUSE RESORTS INC.
ALOT
GRF ASTRONOVA INC.
NHF EAGLE CAPITAL GROWTH FUND INC
BCBP NEXPOINT CREDIT STRATEGIES FUN
RSSS BCB BANCORP INC.
NWPP RESEARCH SOLUTIONS
RFL NEW PEOPLES BANKSHARES INC.
ULBI RAFAEL HOLDINGS CL B
YMAB ULTRALIFE
IMUX Y-MABS THERAPEUTICS
AMPY IMMUNIC INC
INLX AMPLIFY ENERGY
ENX INTELLINETICS
DLHC INC.
COOK EATON VANCE NEW YORK MUNICIPAL BOND FUND
IMRX DALEIGH HOLDINGS CORP
XLO TRAEGER
NVCT INC.
GECC IMMUNEERING CORP
BARK XILIO THERAPEUTICS INC
NNUP NUVECTIS PHARMA INC
ERNA GREAT ELM CAPITAL CORP
GTE ORIGINAL BARK CO
GENK NOCOPI TECHS INC
SRBK ETERNA THERAPEUTICS INC.
NKGN GRAN TIERRA ENERGY INC.
PROP GEN RESTAURANT GROUP INC
ACTU SR BANCORP INC
SUNS NKGEN BIOTECH INC
EVM PRAIRIE OPERATING CO.
MBRX ACTUATE THERAPEUTICS INC.
SLS SUNRISE REALTY TRUST
WHLR EATON VANCE INSD CALIF MUN BD FD
HYMC MOLECULIN BIOTECH INC.
THAR SELLAS LIFE SCIENCES GROUP INC
RVYL WHEELER REAL ESTATE INVESTMENT TRUST INC.
INUV HYCROFT MINING HOLDING CORPORATION
CCIF THARIMMUNE INC.
RYVYL INC.
INUVO INC.
CARLYLE CREDIT INCOME FUND
- Wedbush Research
HPP HUDSON PACIFIC PROPERTIES INC.
UDR UDR INC.
TRNO TERRENO REALTY CORPORATION
STAG STAG INDUSTRIAL INC.
SBRA SABRA HEALTH CARE REIT INC.
RWT REDWOOD TRUST INC.
REXR REXFORD INDUSTRIAL REALTY INC.
OHI OMEGA HEALTHCARE INVESTORS INC.
OFC CORPORATE OFFICE PROPERTIES TRUST
MAA MID-AMERICA APARTMENT COMMUNITIES INC.
WELL WELLTOWER INC.
FR FIRST INDUSTRIAL REALTY TRUST INC.
ESS ESSEX PROPERTY TRUST INC.
EQR EQUITY RESIDENTIAL
EGP EASTGROUP PROPERTIES INC.
CTRE CARETRUST REIT INC
CPT CAMDEN PROPERTY TRUST
BXP BOSTON PROPERTIES INC.
AVB AVALONBAY COMMUNITIES INC.
ARE ALEXANDRIA REAL ESTATE EQUITIES INC.
VTR VENTAS INC.
RC READY CAPITAL CORPORATION
SAFE SAFEHOLD INC.
PEAK HEALTHPEAK PROPERTIES INC.
CSR CENTERSPACE
HR HEALTHCARE TRUST OF AMERICA INC.
Crinetics to Showcase the Next Generation of Endocrinology Innovation ...
Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline Long-term efficacy and safety data on PALSONIFYTM (paltusotine) in acromegaly to be presented, including evidence of both biochemical and symptom control with a well-tolerated safety profile in patients switching treatments and those not previously pharmacologically treated Atumelnant Phase 2 trial results in congenital adrenal hyperplasia (CAH) to be featured in oral presentation Data from early-stage development program in Graves’ hyperthyroidism and orbito...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.